Bio-Rad Buys Sanofi Dx
Executive Summary
Bio-Rad Laboratories is buying Sanofi Diagnostics from Sanofi-Synthelabo in order to increase its mass, goegraphical scope, and diversity of product lines. Bio-Rad, which has life sciences and analytical instruments businesses in addition to a clinical diagnostics business, makes a number of assays and it is looking to increase its presence in infectious diseases, where Sanofi is strong. Sanofi makes tests for infectious diseases and is strong in HIV diagnostics. Burt does Bio-Rad have the wherewithall to make this deal work, given the two companies differ in culture and strengths?